[^1]
[^2]
[^3]
| Symbol | NOVA1 |
| Full Name |
NOVA Alternative Splicing Regulator 1 (Neuro-Oncological Ventral Antigen 1) |
| Chromosome |
14q12 |
| NCBI Gene |
4857 |
| Ensembl |
ENSG00000139910 |
| OMIM |
602157 |
| UniProt |
P51513 |
| Diseases |
[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Paraneoplastic Opsoclonus-Myoclonus Ataxia (POMA) |
| Expression |
[Neurons](/entities/neurons) (hindbrain, ventral spinal cord, [hippocampus](/brain-regions/hippocampus), cortex) |
NOVA1 (NOVA Alternative Splicing Regulator 1), originally identified as Neuro-Oncological Ventral Antigen 1, encodes a neuron-specific RNA-binding protein on chromosome 14q12 that is a master regulator of alternative splicing in the nervous system. NOVA1 was the first mammalian splicing factor identified through its role as the target autoantigen in paraneoplastic opsoclonus-myoclonus ataxia (POMA), a neurological autoimmune syndrome.
NOVA1 regulates the alternative splicing of hundreds of pre-mRNAs encoding synaptic proteins, neurotransmitter receptors, ion channels, and cytoskeletal components. It binds YCAY motifs in pre-mRNA with high specificity, acting as a splicing enhancer or repressor depending on binding position relative to the regulated exon. Together with its paralog NOVA2, NOVA1 orchestrates a neuron-specific splicing program essential for synaptic development, function, and plasticity.
Disruption of NOVA1-dependent splicing has been increasingly implicated in Alzheimer's disease, Parkinson's disease, and ALS, where aberrant RNA processing contributes to synaptic dysfunction and neurodegeneration.
¶ Gene Structure and Protein Products
The NOVA1 gene spans approximately 133 kb on chromosome 14q12, containing 8 exons. The gene itself is subject to alternative splicing, generating multiple isoforms with tissue-specific expression patterns.
The NOVA1 protein (512 amino acids) contains three KH (K-Homology) RNA-binding domains:
- KH1 domain (N-terminal): Contributes to RNA binding specificity
- KH2 domain (central): Primary RNA-binding domain; crystal structure reveals specific YCAY tetranucleotide recognition
- KH3 domain (C-terminal): Participates in RNA binding and protein-protein interactions
- Nuclear localization signal: Directs NOVA1 to the nucleus for co-transcriptional splicing regulation
- Dimerization domain: NOVA1 can form homodimers and heterodimers with NOVA2
NOVA1 recognizes the YCAY motif (where Y = pyrimidine) in pre-mRNA through a well-characterized mechanism:
- KH2 domain makes base-specific contacts with YCAY elements
- Binding affinity increases with clusters of YCAY repeats
- Position of binding relative to the regulated exon determines splicing outcome:
- Upstream intronic binding: Typically promotes exon skipping
- Downstream intronic binding: Typically promotes exon inclusion
- This positional code is known as the "NOVA splicing map"
NOVA1 regulates alternative splicing of a vast network of neuronal transcripts:
- Scope: HITS-CLIP and RNA-seq studies identified ~700 NOVA1-regulated alternative splicing events in mouse brain
- Target classes: Enriched for transcripts encoding synaptic proteins (pre- and post-synaptic), ion channels, cell adhesion molecules, and signaling proteins
- Mechanism: NOVA1 interacts with the spliceosome machinery, including U1 snRNP and core spliceosome components, to modulate splice site selection
NOVA1 regulates the splicing of transcripts critical for neuronal function:
| Target Gene |
Regulated Event |
Functional Consequence |
| GABA(A) receptor γ2 |
Exon 9 (γ2S vs γ2L) |
Modulates receptor trafficking and phosphorylation |
| Glycine receptor α2 |
Exon 3A vs 3B |
Alters receptor kinetics and localization |
| NMDA receptor NR1 |
Exon 5, 21 (N1, C2') |
Affects receptor conductance and trafficking |
| Agrin |
Z exons |
Controls neuromuscular junction formation |
| Neuroligin 1 |
Splice site B |
Regulates excitatory synapse specificity |
| GIRK2 (Kir3.2) |
Exon 1a/1b |
Determines subcellular channel localization |
| Enabled (Enah) |
EVH2 domain exon |
Actin cytoskeleton regulation at synapses |
¶ Synaptic Development and Function
NOVA1 is essential for proper synaptogenesis and synaptic transmission:
- Nova1 knockout mice die postnatally with motor neuron apoptosis and brainstem/spinal cord deficits
- NOVA1 regulates the splicing of adhesion molecules controlling synapse formation
- Alternative splicing of neurotransmitter receptors by NOVA1 tunes inhibitory synaptic transmission
- NOVA1 targets are enriched at both excitatory and inhibitory synapses
Recent work has expanded NOVA1's functions beyond splicing:
- Alternative polyadenylation: NOVA1 regulates 3' UTR length of hundreds of neuronal transcripts, affecting mRNA stability and translation
- RNA localization: Binds 3' UTR YCAY elements to regulate dendritic mRNA transport
- Translational control: Modulates ribosome association of target mRNAs at synapses
NOVA1 was originally identified as the autoantigen in POMA:
- POMA patients develop antibodies against NOVA1 (anti-Ri antibodies) in the context of breast or lung cancer
- The autoimmune response destroys NOVA1-expressing neurons in the brainstem and cerebellum
- Clinical features: chaotic eye movements (opsoclonus), myoclonus, truncal ataxia, and encephalopathy
- Disease mechanism: loss of NOVA1-dependent splicing in affected neurons leads to synaptic dysfunction and cell death
Dysregulated NOVA1 function contributes to splicing abnormalities in Alzheimer's disease:
- Expression changes: NOVA1 protein levels are reduced in AD temporal cortex, correlating with disease severity
- Splicing alterations: Many NOVA1 target exons show altered inclusion levels in AD brain, including glutamate receptor and synaptic adhesion transcripts
- Tau interaction: NOVA1 splicing of MAPT (tau) pre-mRNA regulates exon 10 inclusion, influencing the 3R/4R tau ratio. NOVA1 loss leads to tau mis-splicing, connecting to tauopathy mechanisms
- Amyloid processing: NOVA1 regulates splicing of APP processing machinery, potentially affecting amyloid-beta production
In Parkinson's disease:
- NOVA1 expression declines in dopaminergic neurons of the substantia nigra
- Splicing of dopamine receptor (DRD2) and transporter (DAT/SLC6A3) mRNAs is NOVA1-dependent
- Alpha-synuclein aggregation disrupts nuclear NOVA1 function by sequestering it in cytoplasmic inclusions
- Altered NOVA1-dependent splicing of LRRK2 isoforms may modify PD risk
In ALS:
- NOVA1 target transcripts show widespread splicing disruption in ALS spinal cord
- TDP-43 and NOVA1 co-regulate overlapping sets of neuronal exons; TDP-43 pathology indirectly affects NOVA1 targets
- FUS interacts with NOVA1 to co-regulate RNA processing at synapses
- Motor neuron vulnerability in NOVA1 knockout mice recapitulates aspects of ALS
- NOVA1 regulates splicing of GABA receptor subunits, which are critical for inhibitory neurotransmission
- Loss of NOVA1-dependent GABA receptor splicing disrupts inhibitory/excitatory balance
- Rare NOVA1 variants have been identified in patients with epileptic encephalopathy
NOVA1 shows a restricted expression pattern within the CNS:
- Hindbrain: Highest expression in the brainstem (especially ventral pons and medulla)
- Spinal cord: Ventral horn motor neurons and interneurons
- Subcortical regions: Hypothalamus, thalamus, basal ganglia
- Hippocampus: Moderate expression in CA1-CA3 and dentate gyrus
- Cerebral cortex: Lower expression, primarily in deeper layers
- Cerebellum: Purkinje cells and deep cerebellar nuclei
NOVA1 expression is complementary to NOVA2, which predominates in the cerebral cortex and hippocampus, creating a combined coverage of all major brain regions.
- Exclusively expressed in neurons (not in glia)
- Enriched in inhibitory and motor neurons
- Absent from non-neural tissues (except in some cancers, where ectopic expression triggers autoimmunity)
NOVA1 dysfunction-associated diseases could benefit from RNA-targeted therapies:
- Antisense oligonucleotides (ASOs): ASOs targeting specific NOVA1-regulated exons could correct mis-splicing events in neurodegeneration
- Small molecule splicing modulators: Compounds that modulate NOVA1-dependent splice site selection
- Gene therapy: AAV-mediated NOVA1 restoration in affected brain regions
- NOVA1-dependent splicing patterns in CSF-derived RNA as biomarkers for neurodegenerative disease stage
- Altered ratios of NOVA1-regulated splice variants (e.g., MAPT exon 10 ratio) as disease indicators
- Buckanovich et al., Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein (1993)
- Ule et al., NOVA regulates brain-specific alternative splicing through an RNA map (2006)
- Raj & Bhatt, NOVA1-regulated RNA networks in brain aging and Alzheimer's disease (2018)
- NOVA2 — NOVA alternative splicing regulator 2 (paralog)
- TARDBP — TDP-43 RNA-binding protein (ALS/FTD)
- FUS — Fused in sarcoma RNA-binding protein (ALS)
- MAPT — Microtubule-associated protein tau
- RNA Splicing Defects — Splicing dysfunction in neurodegeneration
- Spliceosome — Pre-mRNA splicing machinery